Revolutionizing Pulmonary Medicine
Advancing Interstitial Lung Disease (ILD) Treatments​
At Pulmonara Labs, we are committed to developing innovative and effective therapies that address the unmet medical needs of patients suffering from various forms of ILD (Interstitial Lung Disease), including idiopathic pulmonary fibrosis, cystic fibrosis and pulmonary hypertension.
We are striving towards the execution of impactful, meaningful
change in the current standard of care for individuals suffering from these respiratory conditions. Breaking the bonds of chronic steroid usage and limited treatment options while reenforcing rigorous standards to allow patients and their families peace of mind and alternative treatment options.
Opportunity
There is significant scientific evidence to support plant-derived therapeutic interventions can provide significant quality-of-life adjustments for individuals suffering from these diseases, while also serving as an alternative to steroid-based treatment options. Most treatments for respiratory diseases are oral drug delivery systems, whereas this product delivers therapeutic agents at the site of the disease.
​
Breaking Steroid Dependency & Unlocking Therapeutic Benefits Through Plant Based Medicines
​
Future drug product analogs developed from plant-derived terpenes can be used to induce extensive therapeutic benefits. The potential for definitive strategies targeting distinct underlying conditions grow in proportion to the rate they are being studied and developed. Additional chemical modifications to already existing plant-derived terpenes can offer access to different biochemical targeting pathways aside from conventional pathways.
​
Pharma. Sector Quality Systems
Furthering the advancement and validation of new and emerging plant derivative drug products under current FDA Regulations for Drug Product R&D, Manufacturing and Testing.
Reliable Research and Development
Finding links between pharmaceutical grade plant derivatives and its ability to be applied as a treatment method for orphan respiratory diseases.
Infiltration & Disruption of Major Drug Product Markets
Market Evaluations spanning billions of dollars across domestic and global markets for each analog product.
Our Journey
How We Got Here
Pulmonara Labs began as a pioneering company based in Philadelphia dedicated to making a profound impact on healthcare through innovative plant-derived terpene research. With a strong commitment to addressing orphan diseases, Pulmonara Labs combines cutting-edge science and the therapeutic potential of plant-derived terpenes to develop groundbreaking solutions. Our mission is not only to advance medical knowledge but also to improve the lives of those suffering from rare and overlooked conditions. Through relentless dedication and a focus on scientific excellence, Pulmonara Labs is at the forefront of redefining the boundaries of plant-derived terpene research.
Where We're Going
The future of Pulmonara Labs holds great promise and potential. As the field of terpene research continues to evolve and gain acceptance, the company is poised to play a pivotal role in advancing the use of terpene-based treatments for orphan diseases. With ongoing research and development, we aim to bring innovative therapies to market, offering hope to patients who have long been underserved by traditional medicine.
University Collaboration
Collaborative efforts with students and faculty at Saint Joseph's University has yielded promising results for our company and its relationship with the Philadelphia community.
​